Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price fell 1.6% during trading on Monday . The company traded as low as $17.05 and last traded at $17.42, with a volume of 89,009 shares. The stock had previously closed at $17.70.

A number of brokerages have commented on NTLA. Wedbush began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 target price for the company. Jefferies Group began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They issued a “hold” rating and a $33.00 target price for the company. Credit Suisse Group AG began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective on the stock. Finally, Leerink Swann began coverage on shares of Intellia Therapeutics in a report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective on the stock.

The stock’s 50-day moving average is $24.12 and its 200-day moving average is $24.82. The company’s market cap is $640.37 million.

In other news, insider Bros. Advisors Lp Baker bought 200,000 shares of the stock in a transaction that occurred on Wednesday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $3,600,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Institutes For Biomed Novartis bought 277,777 shares of the stock in a transaction that occurred on Wednesday, May 11th. The shares were purchased at an average price of $18.00 per share, with a total value of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.